Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412865 | 0.95 | CRHR1 (0.57) | CRHR1HSP90AB1TLR8 | |
| SCHEMBL5421181 | 0.84 | CRHR1 (0.48) | CRHR1HSP90AB1TLR8CTSA | |
| SCHEMBL7483586 | 0.79 | TLR8 (0.41) | CRHR1HSP90AB1TLR8 | |
| SCHEMBL5406493 | 0.78 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5417534 | 0.77 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL5414876 | 0.77 | CRHR1 (0.82) | CRHR1 | |
| SCHEMBL5404638 | 0.75 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5433663 | 0.75 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL5409833 | 0.74 | CRHR1 (0.63) | CRHR1 | |
| SCHEMBL5416470 | 0.74 | CRHR1 (0.60) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885HSP90AB1 2799/4885TLR8 1197/4885 |
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885HSP90AB1 2799/4885TLR8 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.